Quarterly report [Sections 13 or 15(d)]

Segment Information - Schedule of financial information regularly reviewed and used by the CODM (Details)

v3.25.3
Segment Information - Schedule of financial information regularly reviewed and used by the CODM (Details) - USD ($)
 3 Months Ended 9 Months Ended
Feb. 21, 2025
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2025
Sep. 30, 2024
Research and development (excluding stock-based compensation) expense:                  
PAH   $ 5,598,722     $ 814,424     $ 17,668,360 [1] $ 815,474 [1]
Parkinson's disease   323,301     2,776,009     507,917 7,786,014
Other research and development   55,114     515,070     1,476,385 1,320,900
Selling, general and administrative (excluding stock-based compensation)   2,758,857     1,573,949     9,785,962 5,505,825
Change in fair value contingent consideration $ (4,435,443) (492,827)     0     (2,016,111) 0
Stock-based compensation expense   4,525,206     148,024     10,776,144 232,155
Total costs and expenses   12,768,373     5,827,476     38,198,657 15,660,368
Loss from operations   (12,768,373)     (5,827,476)     (38,198,657) (15,660,368)
Interest income   838,093     49,410     2,674,119 273,059
Net loss   (11,930,280) $ (9,915,523) $ (13,678,735) (5,778,066) $ (4,959,608) $ (4,649,635) (35,524,538) (15,387,309)
Operating Segment                  
Research and development (excluding stock-based compensation) expense:                  
Stock-based compensation expense   $ 4,525,206     $ 148,024     $ 10,776,144 $ 232,155
[1] This amount includes a one-time (non-cash) charge of $7.4 million for the acquired IPR&D related to the CorHepta acquisition.